Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EMLA vs FLAGYL ER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EMLA is a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%. Lidocaine and prilocaine are amide-type local anesthetics that block sodium ion channels in neuronal membranes, inhibiting the initiation and conduction of nerve impulses, thereby producing local analgesia.
Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.
Topical anesthesia of intact skin for superficial procedures,Topical anesthesia of genital mucous membranes for minor superficial procedures,Local analgesia prior to lumbar puncture (off-label),Local analgesia prior to vaccination (off-label)
Treatment of bacterial vaginosis (FDA-approved),Off-label: Clostridium difficile infection, anaerobic infections, trichomoniasis, amebiasis, giardiasis, rosacea, periodontal disease, Helicobacter pylori eradication
Apply a thick layer of cream (approximately 2.5 g per 20 cm²) to intact skin under an occlusive dressing for at least 1 hour for minor procedures; for dermal procedures on larger areas, apply up to 60 minutes before procedure, maximum single application area of 600 cm² in adults.
750 mg orally once daily for 10 days for bacterial vaginosis.
After topical application, the terminal elimination half-life of lidocaine is approximately 1.5-2 hours; prilocaine half-life is approximately 1.5 hours. In neonates, half-life may be prolonged due to immature hepatic function. Clinical context: Steady state is achieved within 12-24 hours with repeated application.
Terminal elimination half-life: 6-8 hours (increased to 10-12 hours with hepatic impairment; unchanged in renal impairment).
Lidocaine is primarily metabolized by CYP1A2 to monoethylglycinexylidide (MEGX) and further by CYP3A4; prilocaine is metabolized by amidases to o-toluidine metabolites that can oxidize hemoglobin to methemoglobin.
Hepatic metabolism via side-chain oxidation and glucuronidation; metabolites are 5-nitroimidazoles and hydroxy metabolites; CYP450 enzymes (CYP2A6, CYP3A4, CYP2B6) partially involved.
Lidocaine and prilocaine are metabolized in the liver; lidocaine metabolites (primarily 4-hydroxyxylidine) and prilocaine metabolites (primarily o-toluidine) are excreted renally. Less than 5% of unchanged lidocaine and prilocaine are excreted unchanged in urine. Fecal excretion is negligible.
Renal: 60-80% (metabolites and unchanged drug). Fecal: 6-15%. Minimal biliary.
Lidocaine: 65-70% bound to alpha-1-acid glycoprotein and albumin. Prilocaine: 55% bound to albumin.
<20% (albumin).
Lidocaine: Vd approximately 1.0-1.5 L/kg; prilocaine: Vd approximately 1.5-2.0 L/kg. Clinical meaning: Large Vd indicates extensive tissue distribution, including into the CNS and adipose tissue.
0.5-0.8 L/kg; indicates extensive tissue distribution including CNS.
Topical bioavailability: 20-30% for lidocaine and prilocaine when applied to intact skin under occlusion; higher (up to 80%) on mucous membranes or abraded skin. Systemic absorption is minimal with recommended doses, but can be significant with prolonged application or large surface areas.
Oral: 80-95% (extended-release formulation).
No dose adjustment required for renal impairment; however, use with caution in patients with severe renal impairment due to potential accumulation of lidocaine and prilocaine metabolites.
No adjustment necessary for GFR >10 m L/min; for GFR <10 m L/min, consider using immediate-release metronidazole instead of FLAGYL ER due to lack of data in severe renal impairment.
In Child-Pugh Class B or C, use with caution and consider reduced application area or shorter application time due to reduced metabolism of lidocaine and prilocaine; specific dose modifications not established.
Child-Pugh Class A/B: no adjustment necessary. Child-Pugh Class C: reduce dose to 375 mg orally once daily (50% of usual dose).
Infants and children: Apply 1-2 g per 10 cm², with maximum application area based on weight: 10 cm² for infants 1-3 months, 20 cm² for 3-12 months, 100 cm² for 1-6 years, 200 cm² for 7-12 years; application time 30-60 minutes depending on age and procedure.
Safety and efficacy not established for FLAGYL ER in pediatric patients. Use immediate-release metronidazole for pediatric dosing.
No specific dose adjustment; use with caution in elderly due to increased risk of systemic absorption from thinner skin and potential comorbidities; consider smaller application area or shorter duration.
No specific dose adjustment recommended based on age alone; use caution due to potential for decreased renal function and monitor for adverse effects.
EMLA cream can cause methemoglobinemia, especially in children under 12 months, patients with glucose-6-phosphate dehydrogenase deficiency, or those taking oxidizing drugs. Serious and fatal methemoglobinemia has been reported; monitor for signs and symptoms.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Avoid chronic use. Reserved for anaerobic and protozoal infections.
Avoid application to open wounds, mucous membranes (except genital), or areas with altered skin barrier. Use with caution in patients with severely traumatized mucosa or sepsis. Monitor for methemoglobinemia, especially in young children. Do not apply to large areas or for prolonged periods. Consider risk of systemic toxicity if applied to inflamed skin or large areas.
Peripheral neuropathy (risk with prolonged use), CNS effects (seizures, encephalopathy), disulfiram-like reaction with alcohol, sodium overload (each tablet contains 84 mg sodium), hepatic impairment may increase risk of toxicity, renal impairment (dose adjustment not typically required but monitor), superinfection including C. difficile diarrhea.
Hypersensitivity to lidocaine, prilocaine, or other amide anesthetics; known history of methemoglobinemia; application to eyes or on tympanic membrane; patients with severe hepatic disease (due to impaired metabolism).
Hypersensitivity to metronidazole or other nitroimidazoles; concurrent use of disulfiram (psychotic reactions); caution in pregnancy (first trimester only if clearly needed; crosses placenta); breastfeeding (use caution due to potential carcinogenicity).
No known food interactions. Avoid alcohol if large amounts of lidocaine/prilocaine are absorbed (rare).
Avoid alcohol and any products containing alcohol (e.g., mouthwash, cough syrups, cooking wine) during therapy and for 48 hours after last dose. No specific food restrictions otherwise.
EMLA (lidocaine 2.5% and prilocaine 2.5%) is FDA Pregnancy Category B. Lidocaine and prilocaine cross the placenta. In first trimester, no increased risk of major malformations in human data. Second and third trimesters: no known fetal harm from topical use. Methemoglobinemia risk in fetus if high doses or prolonged use, especially with prilocaine.
Trimester 1: Crosses placenta; contraindicated in first trimester due to risk of carcinogenicity in animal studies and potential teratogenicity; use only for life-threatening infections. Trimester 2 and 3: Use with caution; associated with increased risk of cleft lip/palate in some studies; avoid if possible.
Lidocaine and prilocaine are excreted into breast milk in low amounts. M/P ratio: lidocaine ~0.4-0.6, prilocaine ~1.0-1.4. Infant dose ~1-2% of maternal weight-adjusted dose. Risk of methemoglobinemia in premature or G6PD-deficient infants. Use with caution.
Excreted in breast milk; M/P ratio ~0.9; American Academy of Pediatrics considers compatible with breastfeeding, but advise caution; monitor infant for diarrhea or oral thrush.
No specific dose adjustments required for topical application. Physiologic changes in pregnancy (increased plasma volume, decreased protein binding) do not significantly alter systemic absorption from intact skin. Avoid large areas, prolonged application, or abraded skin to minimize systemic load.
No specific dose adjustments recommended based on pregnancy pharmacokinetics; however, due to increased GFR in pregnancy, consider monitoring therapeutic levels for severe infections.
EMLA (eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) requires at least 60 minutes of occlusive application for dermal analgesia. Apply to intact skin only; avoid mucous membranes due to rapid absorption. Do not use in infants <37 weeks postconceptual age due to methemoglobinemia risk. Maximum application area: 10% body surface in infants. Onset is slower on thicker skin (e.g., back vs. antecubital). Remove cream after 4 hours to prevent systemic toxicity.
FLAGYL ER (metronidazole extended-release) is indicated for bacterial vaginosis. Avoid alcohol during therapy and for 48 hours after completion due to disulfiram-like reaction. Monitor for peripheral neuropathy; discontinue if signs occur. Use with caution in hepatic impairment; dose adjustment may be needed. May cause metallic taste.
Apply a thick layer (1-2 mm) to intact skin and cover with occlusive dressing for at least 60 minutes before procedure.,Do not use on broken skin, eyes, or near mucous membranes.,Wash hands after application and avoid touching eyes.,Remove cream and dressing just before procedure; do not leave on longer than 4 hours.,Possible mild skin reactions: blanching, redness, swelling. Serious allergic reactions are rare but seek medical help if difficulty breathing or hives occur.,Inform your doctor if you have liver disease, G6PD deficiency, or are taking other numbing medicines.
Take this medication exactly as prescribed; do not crush or chew the extended-release tablets.,Avoid all alcohol and alcohol-containing products during treatment and for 48 hours after the last dose to prevent severe nausea, vomiting, and flushing.,Complete the full course even if symptoms improve to ensure infection is fully treated.,Report any numbness, tingling, or pain in hands or feet to your doctor immediately.,Inform your healthcare provider if you have liver disease, a history of blood disorders, or are pregnant or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EMLA vs FLAGYL ER, answered by our medical review team.
EMLA is a Local Anesthetic that works by EMLA is a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%. Lidocaine and prilocaine are amide-type local anesthetics that block sodium ion channels in neuronal membranes, inhibiting the initiation and conduction of nerve impulses, thereby producing local analgesia.. FLAGYL ER is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EMLA and FLAGYL ER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EMLA is: Apply a thick layer of cream (approximately 2.5 g per 20 cm²) to intact skin under an occlusive dressing for at least 1 hour for minor procedures; for dermal procedures on larger areas, apply up to 60 minutes before procedure, maximum single application area of 600 cm² in adults.. The standard adult dose of FLAGYL ER is: 750 mg orally once daily for 10 days for bacterial vaginosis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EMLA and FLAGYL ER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EMLA is classified as Category C. EMLA (lidocaine 2.5% and prilocaine 2.5%) is FDA Pregnancy Category B. Lidocaine and prilocaine cross the placenta. In first trimester, no increased risk of major malformations in . FLAGYL ER is classified as Category C. Trimester 1: Crosses placenta; contraindicated in first trimester due to risk of carcinogenicity in animal studies and potential teratogenicity; use only for life-threatening infec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.